Zai Lab Q1 2026 Revenue Misses Estimates Despite Pipeline Progress

Zai Lab Ltd reported its first-quarter 2026 financial results on May 7, with total revenue falling 6% year-over-year to $99.6 million, missing analyst expectations of $117.97 million by 15.56%. The company delivered an earnings beat with EPS of -$0.05 versus the forecasted -$0.47, and shares declined 2.33% in premarket trading to $20.50.

The company highlighted significant advances in its global oncology pipeline, particularly for lead candidate zocilurtatug pelitecan (Zoci), a DLL3-targeting antibody-drug conjugate. Data presented at the American Association for Cancer Research (AACR) 2026 conference showed a 62.5% confirmed intracranial overall response rate at the 1.6 mg/kg dose in patients with brain metastases, including 25% complete intracranial responses. The safety profile showed only 16.4% of patients experiencing Grade ≥3 treatment-related adverse events, compared with 36.5% for I-Dxd and 49.0% for ABBV-706.

Zai Lab has development collaborations with Amgen and Boehringer Ingelheim to evaluate Zoci in combinations with DLL3 T-cell engagers. The global Phase 3 DLLEVATE study is enrolling 480 patients with second- and third-line small cell lung cancer, with enrollment completion expected in the first half of 2027 and an interim analysis planned for 2027 that could support an accelerated approval submission to the FDA. In extrapulmonary neuroendocrine carcinomas, Zoci demonstrated a 38.2% overall confirmed response rate, and the company plans to finalize a registrational path with the FDA and advance into a registration-enabling study by year-end 2026. Three pivotal trials are expected by year-end 2026, including the ongoing Phase 3 DLLEVATE monotherapy study, planned Phase 1 combination studies with PD-L1 inhibitors and chemotherapy, and partner-sponsored studies with Amgen's tarlatamab and Boehringer Ingelheim's obrixtamig.

The revenue decline was driven primarily by a 39% year-over-year drop in ZEJULA sales to $30.0 million from $49.5 million. Other products showed mixed results:

• XACDURO revenue surged 667% to $8.6 million.
• NUZYRA grew 8% to $16.3 million.
• QINLOCK and OPTUNE each grew 6% to $9.0 million and $12.0 million, respectively.
• VYVGART/VYVGART Hytrulo declined 3% to $17.6 million.

Product revenue net totaled $95.6 million, down 10% year-over-year, while collaboration revenue jumped 384% to $4.0 million. The loss from operations increased 23% to $69.4 million, reflecting higher R&D and SG&A expenses. Zai Lab maintained a cash position of $761.3 million as of March 31, 2026.

Beyond Zoci, ZL-1503, a potential first-in-class bispecific antibody targeting both IL-13 and IL-31 pathways for atopic dermatitis, is advancing through a Phase 1/1b study with first-in-human data expected in the second half of 2026. ZL-6201, an LRRC15-targeted ADC for sarcoma and other solid tumors, has initiated a global Phase 1 study.